Introduction
============

Traumatic thoracolumbar spinal cord injury (TLSCI) is an important healthcare issue that could affects thousands of individuals annually worldwide. The mortality rate is one of the important indicators of economic and social burdens of a disease. Treatment outcomes can also be evaluated using the rate of mortality. Additionally, more accurate data such as in-hospital mortality may be indicators of health system quality and play a major role in management decision making. Although the age and cause of injury are not different in thoracolumbar and cervical levels, complications and mortality rates are higher in cervical spinal cord injuries than thoracolumbar levels \[[@B1]-[@B6]\]. Thoracolumbar vertebral fractures occur most frequently between the levels of T12 to L2 \[[@B7]\] and associated neurological deficits are found with 15 -- 20% of all thoracolumbar injuries \[[@B8]\]. Cardiovascular, infectious, and respiratory disorders had a great role in the mortality of patients with TLSCI. However, advances in medical care have led to a lower rate of the mortality in the 21st century \[[@B9]\]. The mortality rate associated with TLSCI in different countries is an important subject. However, there is no comprehensive study to show the global picture of the mortality of TLSCI.According to the literature, the level of the lesion, the neurological status (complete or incomplete injury), age, gender, joint injuries, comorbidities, and time from injury to treatment are all factors affecting mortality in patients with spinal cord injury (SCI) \[[@B10]\]. In current work, we attempted to evaluate and, to the extent possible, pool all homogenous studies to estimate the overall mortality rate and contributing factors in patients with TLSCI. To the best of the authors' knowledge at the time of submission, this is the first systematic review that has explicitly evaluated mortality rate after thoracolumbar SCI.

Materials and Methods
=====================

 *Search strategy*

 A systematic review of patients with TLSCI was performed to define mortality rate and its contributing factors. The review and its analysis were carried out in accordance to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@B11]\] and the search strategy was designed by a medical information specialist ([Figure 1](#F1){ref-type="fig"}). The MEDLINE and EMBASE (via Ovid) databases were queried on February 6, 2016, without limitation for document type, or publication status. However, studies were excluded if not written in the English language or reported before 1997. Keywords were searched ([Figure 1](#F1){ref-type="fig"}) as well as the review of the initial search results and citations of included articles. Because relevant outcome measures are not always mentioned in fields that may be queried for all reports, no specific issue term was used to augment the search results; instead, the outcomes were sought for after acquiring the full-text of the available results. The results of this query were then entered into Endnote X5 and sent to two independent reviewers.

![Search strategy design](bet-6-181-g001){#F1}

*Inclusion and Exclusion criteria*

 The inclusion criteria were as follows: the study was conducted on patients with distinct, definite TLSCI as the main study group or sub-group; traumatic status was established; death was considered as an outcome, and the cohort consisted of at least 20 patients. Studies with age, gender, and functional limitations and those conducted on a particular population were excluded. Reports not written in the English language and those where only the abstract was available were excluded. Studies carried out on January 1, 1997, were excluded.

*Data extraction*

 The titles, abstracts, and full-texts of available reports were checked by two independent reviewers against the criteria as mentioned earlier. Any disagreements on article selection were solved through discussion. Where the records were unclear or incompetent, attempts were made to contact the authors by email. There was only one response to our emails.

Two reviewers separately assessed the quality of the selected studies according to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group \[[@B12]\], which was designed for observational studies and used in previous systematic reviews \[[@B13]-[@B16]\] ([Table 1](#T1){ref-type="table"}). The studies were categorized into quality levels according to the methodological quality score ([Table 2](#T2){ref-type="table"}).

###### 

Criteria for Assessment of the Methodological Quality of Observational Studies.

  **Item**                                              **Criterion**                                                                                                                                                                                                 **Score**
  ----------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  **Study population**                                  Sample size ≥ 50 and participation rate≥ 80%                                                                                                                                                                  1
  **Patient selection**                                 For cohort studies: cases and controls draw from the same population; for cross-sectional and case-series studies: selected group was representative of the TLSCI[a](#TFN1){ref-type="table-fn"} population   1
  **Study design**                                      Cohort design                                                                                                                                                                                                 2
  Retrospective case-series or cross-sectional design   1                                                                                                                                                                                                             
  Reported the duration of follow-up                    1                                                                                                                                                                                                             
  Study withdrawal rate ≤ 20%                           1                                                                                                                                                                                                             
  **Analysis and data presentation**                    Appropriate analysis techniques were used                                                                                                                                                                     1
  Multivariate analysis performed                       1                                                                                                                                                                                                             
  Frequencies of most important outcomes were given     1                                                                                                                                                                                                             

Thoracolumbar spinal cord injury.

###### 

Criteria for Assessment of Quality of the Included Studies

  **Item**                                                        **Level**                                                         **Criteria for Inclusion**
  --------------------------------------------------------------- ----------------------------------------------------------------- -------------------------------------------------------------
  **Level of studies**                                            High-quality studies                                              Multivariate analysis performed and had a quality score ≥ 7
  Moderate-quality studies                                        Multivariate analysis performed, but had a quality score \< 7     
  No multivariate analysis performed and had a quality score≥ 4                                                                     
  Low-quality studies                                             No multivariate analysis performed and had a quality score \< 4   

Two independent reviewers extracted data including the study type and duration, demographics, male to female ratio, mean age at the time of injury, and assessment period. Because any potentially confounding factors affecting mortality are peculiar to the particular study, these factors (comorbidities and coexisting injuries) were included, similar to previous systematic reviews \[[@B17], [@B18]\].

Reports examining the association between risk factors and mortality were found. Since the essential characteristics were not homogenous across all studies, a meta-analysis was not performed. However, the mean number of death for studies with similar follow-up period was calculated.

Results
=======

The search strategy yielded 6796 records. After screening the titles and abstracts, 138 articles were selected for full-text assessment; 114 of these were excluded. After application of all inclusion and exclusion criteria, a total of 24 studies were selected for systematic review ([Figure 2](#F2){ref-type="fig"}). The characteristics of the selected studies are shown in [Table 3](#T3){ref-type="table"}. The articles were published from January 1, 1997, to February 6, 2016.  The population sizes ranged from 22 subjects to 4042 patients. Eight studies were from North America (6 from the United States, two from Canada), one from Latin America (Brazil), three from Oceania (Australia), five from European countries, four from the African region, and three from Asian countries. Concomitant traumatic injuries and comorbidities were stated in just 8 and four reports, respectively; however, in all of these reports, these factors were described for the total study population and not for the thoracolumbar patients exclusively.

![Flowchart of Studies Excluded and Included for Systematic Review.](bet-6-181-g002){#F2}

###### 

Characteristics of the Selected Studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Studies**                                  **Country**                               **Study period**   **Design**                               **Sample size**   **M/F**                                  **Mean age(years)**                             **Co-injuries**                                                                                 **PECs**q                                            **Mortality**   **SMR**r
  -------------------------------------------- ----------------------------------------- ------------------ ---------------------------------------- ----------------- ---------------------------------------- ----------------------------------------------- ----------------------------------------------------------------------------------------------- ---------------------------------------------------- --------------- -------------------------------------
  **Krause 1997 \[** [@B37] **\]**             United States                             1985-1996          Prospective cohort                       141               4.3/1[a](#TFN2){ref-type="table-fn"}     24.5±10.9 [a](#TFN2){ref-type="table-fn"}       NA[b](#TFN3){ref-type="table-fn"}                                                               NA[b](#TFN3){ref-type="table-fn"}                    13.5%           NA[b](#TFN3){ref-type="table-fn"}

  **Levy 1998 \[** [@B19] **\]**               Zimbabwe                                  1988_1994          Retrospective case-series                67                7.4/1                                    NA[b](#TFN3){ref-type="table-fn"}               NA[b](#TFN3){ref-type="table-fn"}                                                               NA[b](#TFN3){ref-type="table-fn"}                    19.4%           NA^[b](#TFN3){ref-type="table-fn"}^

  **Yeo 1998 \[** [@B6] **\]**                 Australi[a](#TFN2){ref-type="table-fn"}   1955-1994          Retrospective cohort                     650               4.5/1 [a](#TFN2){ref-type="table-fn"}    NA[b](#TFN3){ref-type="table-fn"}               NA[b](#TFN3){ref-type="table-fn"}                                                               NA[b](#TFN3){ref-type="table-fn"}                    17.4%           1.9(1.5-2.3)

  **O'Connor2005** **\[**[@B5]**\]**           Australi[a](#TFN2){ref-type="table-fn"}   1986-1997          Cohort study                             1355              4.01/1                                    \                                                                                                                                                                                                                    
                                                                                                                                                                                                                NA[b](#TFN3){ref-type="table-fn"}                                                                                                                                                                                    

  **Lidal 2007\[** [@B9] **\]**                Norway                                    1961-1982          Retrospective                            205               3.54:1                                   25.3                                                                                                                                                                                                 37%             Men:1.3women:3.3

  **Leal-Filho 2008** **\[**[@B38]**\]**       Brazil                                    1995_2002          Prospective cohort                       189               6.3/1 [a](#TFN2){ref-type="table-fn"}    NA[b](#TFN3){ref-type="table-fn"}               NA[b](#TFN3){ref-type="table-fn"}                                                               NA[b](#TFN3){ref-type="table-fn"}                    0               NA[b](#TFN3){ref-type="table-fn"}

  **Furlan 2009** **\[**[@B23]**\]**           Canada                                    1996-2007          Retrospective cohort                     87                2.7/1 [a](#TFN2){ref-type="table-fn"}    52.1 [a](#TFN2){ref-type="table-fn"}            NA[b](#TFN3){ref-type="table-fn"}                                                               Mean CCIs, Mean CIRSt, Mean number of ICD-9o codes   2.3%            NA[b](#TFN3){ref-type="table-fn"}

  **Divanoglou 2010** **\[**[@B30]**\]**       Sweden Greece                             2006_2007          Prospective Population-Based Study       48                NA[b](#TFN3){ref-type="table-fn"}        NA[b](#TFN3){ref-type="table-fn"}               Extraspinal Injuries (Skull, Thorax, Pelvis)                                                    CVDe, Spinal stenosis, ASh, Degenerative             6.3%            NA[b](#TFN3){ref-type="table-fn"}

  **Furlan 2010** **\[**[@B25]**\]**           Canada                                    NA                 Prospective cohort                       136               5.3/1 [a](#TFN2){ref-type="table-fn"}    NA                                              GCSm                                                                                            NA[b](#TFN3){ref-type="table-fn"}                    4.4%            NA[b](#TFN3){ref-type="table-fn"}

  **Hagen 2010** **\[**[@B20]**\]**            Norway                                    1952_2001          Retrospective cohort                     188               4.7/1 [a](#TFN2){ref-type="table-fn"}    35.2                                            NA[b](#TFN3){ref-type="table-fn"}                                                               NA[b](#TFN3){ref-type="table-fn"}                    31.4%           1.94 (1.51, 2.51)

  **Ning 2011** **\[**[@B39]**\]**             China                                     2004-2008          Retrospective                            248               5.6/1                                    46                                                                                                                                                                                                   0                

  **Varma 2010** **\[**[@B10]**\]**            United States                             1993-2003          Retrospective cohort                     715               3/1 [a](#TFN2){ref-type="table-fn"}      Median age:41[a](#TFN2){ref-type="table-fn"}    TBIg,ISSl                                                                                       NA[b](#TFN3){ref-type="table-fn"}                    10.3%           NA[b](#TFN3){ref-type="table-fn"}

  **Ahoniemi 2011** **\[**[@B1]**\]**          Finland                                   1976-2007          Retrospective                            811               3.77:1                                   Male:34.5 female:33.2                                                                                                                                                                                4.06%           2.97

  **Krause 2011** **\[**[@B27]**\]**           United States                             1998-2008          Prospective cohort                       402               2.9:1 [a](#TFN2){ref-type="table-fn"}    31.1±13.5[a](#TFN2){ref-type="table-fn"}        NA[b](#TFN3){ref-type="table-fn"}                                                               NA[b](#TFN3){ref-type="table-fn"}                    20.9%           NA[b](#TFN3){ref-type="table-fn"}

  **Krause 2011** **\[**[@B28]**\]**           United States                             1995-2006          Retrospective cohort                     3990              3.9:1 [a](#TFN2){ref-type="table-fn"}    NA[b](#TFN3){ref-type="table-fn"}               NA[b](#TFN3){ref-type="table-fn"}                                                               NA[b](#TFN3){ref-type="table-fn"}                    10%             NA[b](#TFN3){ref-type="table-fn"}

  **Kawu 2011** **\[**[@B32]**\]**             Nigeria                                   1997-2007          Retrospective cohort                     94                4.6/1 [a](#TFN2){ref-type="table-fn"}    37.2±14.2 [a](#TFN2){ref-type="table-fn"}       GCSm                                                                                            NA[b](#TFN3){ref-type="table-fn"}                    34%             NA[b](#TFN3){ref-type="table-fn"}

  **Grossman 2012** **\[**[@B40]**\]**         United states                             2005-2010          Prospective cohort                       56                3.7:1 [a](#TFN2){ref-type="table-fn"}    44.6±17.1 [a](#TFN2){ref-type="table-fn"}        GCSm,AISp                                                                                      HTj, Diabetes mellitus, hepatitis C                  0               NA[b](#TFN3){ref-type="table-fn"}

  **Middleton 2012** **\[**[@B41]**\]**        Australia                                 1955 -2006         Retrospective cohort                     938               4.5:1 [a](#TFN2){ref-type="table-fn"}    34±17.4 [a](#TFN2){ref-type="table-fn"}         NA[b](#TFN3){ref-type="table-fn"}                                                               NA[b](#TFN3){ref-type="table-fn"}                    21.3%           1.7

  **Cao 2013** **\[**[@B42]**\]**              United States                             1995-2006          Cohort                                   4042              3.88:1 [a](#TFN2){ref-type="table-fn"}   NA[b](#TFN3){ref-type="table-fn"}                                                                                                                                                                                     

  **Nwankwo 2013** **\[**[@B26]**\]**          Nigeria                                   2009-2012          Retrospective case-series                40                4.3:1 [a](#TFN2){ref-type="table-fn"}    34.8±3.3 [a](#TFN2){ref-type="table-fn"}        Chest lesion/long bone fx/ head injury/ abdomen lesion                                          NA[b](#TFN3){ref-type="table-fn"}                    7.5%            NA[b](#TFN3){ref-type="table-fn"}

  **Sabre 2013** **\[**[@B24]**\]**            Estonia                                   1997 -2011         Retrospective cohort                     205                                                        NA[b](#TFN3){ref-type="table-fn"}               Head injury, ATId                                                                               NA[b](#TFN3){ref-type="table-fn"}                    21.5%           NA[b](#TFN3){ref-type="table-fn"}

  **Löfvenmark** **2014** **\[**[@B43]**\]**   Botswana                                  2011 2013          Descriptive cross-sectional              20                2.5:1 [a](#TFN2){ref-type="table-fn"}    80% ⩽45 years [a](#TFN2){ref-type="table-fn"}   fractures in upper and lower extremities, as well as ribs,abdominal injuries and head trauma.   HIVhypertension                                      27.2%           NA[b](#TFN3){ref-type="table-fn"}

  **Barman 2014** **\[**[@B29]**\]**           India                                     1981 -2011         Retrospective cohort                     367               8.6:1 [a](#TFN2){ref-type="table-fn"}    Median age:31 [a](#TFN2){ref-type="table-fn"}   NA[b](#TFN3){ref-type="table-fn"}                                                               NA[b](#TFN3){ref-type="table-fn"}                    25.3%           NA[b](#TFN3){ref-type="table-fn"}

  **Hossain2015** **\[**[@B44]**\]**           Bangladesh                                2011-2014          Mixed retrospective-prospective cohort   201               8,51:1 [a](#TFN2){ref-type="table-fn"}   34 (25--44) [a](#TFN2){ref-type="table-fn"}     NA[b](#TFN3){ref-type="table-fn"}                                                               NA[b](#TFN3){ref-type="table-fn"}                    12.43%          NA[b](#TFN3){ref-type="table-fn"}
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The data for all patients with cervical and thoracolumbar spinal cord injury;

NA: not available;

CHI: closed head injury;

ATI: associated traumatic injury;

CVD: cardiovascular disease;

PD: pulmonary disease;

TBI: traumatic brain injury;

AS: ankylosing spondylitis;

OPLL: ossification of posterior longitudinal ligament;

HT: hypertension;

OA: osteoarthritis;

ISS: Injury Severity Score;

GCS: Glasgow Coma Scale;

GI disease: gastrointestinal disease;

ICD-9 codes: international classification of disease-ninth revision;

AIS: Abbreviated Injury Scale;

PECs: Preexisting co-morbidity;

SMR: standardized mortality ratio;

CCI: Charlson Comorbidity Index;

CIRS: Cumulative Index Rating Scale;

AS: Ankylosing Spondylitis.

The quality of the studies is shown in [Table 4](#T4){ref-type="table"}. All studies had predefined patient inclusion criteria. In 13 studies, the contributing factors for mortality were analyzed. Also in 13 studies, mortality for patients with TLSCI was assessed according to age, gender, ASIA (American Spinal Injury Association) grade, Frankel grade, and level of thoracolumbar spine injury. In eight studies survival rate and four studies, life expectancy was reported as separate outcomes. In just one study, causes of mortality were reported separately for patients with TLSCI. According to methodological quality ([Table 1](#T1){ref-type="table"}), three studies had nine points, nine studies had eight points, two studies had seven points, eight studies had six points, one study had 5 points, and one study had four points. Therefore, ten studies were high-quality (41.6% of studies), 13 studies were moderate quality (54.2 %), and one study was low-quality (4.2%) ([Table 4](#T4){ref-type="table"}).

###### 

Quality Assessment of the Selected Studies.

  **No.**   **Studies**       **Study** **Population**   **Patient** **Selection**   **Study Design**   **Analysis and Data** **Presentation**   **Total Score**   **Level of Studies**
  --------- ----------------- -------------------------- --------------------------- ------------------ ---------------------------------------- ----------------- ----------------------
  1         Krause 1997       0                          1                           4                  3                                        8                 High
  2         Levy 1998         1                          1                           2                  0                                        4                 Low
  3         Yeo 1998          1                          1                           3                  1                                        6                 Moderate
  4         O'Connor 2005     1                          1                           3                  3                                        8                 High
  5         Lidal 2007        1                          1                           3                  2                                        7                 moderate
  6         Leal-Filho 2008   1                          1                           3                  1                                        6                 Moderate
  7         Furlan 2009       1                          1                           3                  3                                        8                 High
  8         Divanoglou 2010   1                          1                           3                  1                                        6                 Moderate
  9         Furlan 2010       1                          1                           4                  3                                        9                 High
  10        Hagen 2010        1                          1                           3                  3                                        8                 High
  11        Ning 2010         1                          1                           3                  1                                        6                 Moderate
  12        Varma 2010        1                          1                           3                  3                                        8                 High
  13        Ahoniemi 2011     1                          1                           3                  1                                        6                 Moderate
  14        Krause 2011       1                          1                           3                  3                                        8                 High
  15        Krause 2011       1                          1                           4                  3                                        9                 High
  16        Kawu 2011         1                          1                           3                  1                                        6                 Moderate
  17        Grossman 2012     1                          1                           3                  2                                        7                 Moderate
  18        Middleton 2012    1                          1                           4                  2                                        8                 Moderatea
  19        Cao 2013          1                          1                           4                  3                                        9                 High
  20        Nwankwo 2013      1                          1                           2                  1                                        5                 Moderate
  21        Sabre 2013        1                          1                           2                  2                                        6                 Moderate
  22        Löfvenmark 2014   0                          1                           3                  2                                        6                 moderate
  23        Barman2014        1                          1                           3                  3                                        8                 High
  24        Hossain 2015      1                          1                           4                  2                                        8                 Moderatea

Multivariate analysis has been performed;

Multivariate analysis has not been performed

*Demographic data*

 Although all studies reported male to female ratio (M/F), M/F was reported for the TLSCI subgroup specifically in just one study \[[@B19]\] while in the other studies M/F was presented for the SCI patients overall. Generally speaking, men were more often affected by SCI. In the study that specifically mentioned M/F in TLSCI patients, it was reported as 7.37 \[[@B19]\]. The mean age was reported in twelve studies and just one study \[[@B20]\] reported the mean age for the thoracolumbar subgroup (35.2 years). One study was performed only among the elderly population \[[@B21]\] and one study was in children \[[@B22]\].

*Mortality rate* [Table 5](#T5){ref-type="table"} demonstrates the mortality rate of all patients with TLSCI and the related causes of death during follow-up. Mortality causes for TLSCI cases were identified in only two studies; the reported mortality rate ranged from 0% to 37.7% disregarding follow-up duration. None of the articles reported the pre-hospital mortality rate. Four reports mentioned the short-term and long-term mortality; eight reported short including in-hospital mortality, and 11 described long-term and post-discharge mortality. In studies relating the in-hospital mortality rate, the duration of hospitalization was not reported (one study mentioned this was less than three months), and the reported death rates ranged from 0 to 10.34 percent. Excluding the pediatric study, four studies evaluated mortality rates after initial hospital admission including 1047 cases; among them 76 patients (7.2%) died. Furlan *et al*., \[[@B23]\] reported an in-hospital mortality rate of 5.7% of the overall SCI population and 2.3% of patients with TLSCI.

 [Table 6](#T6){ref-type="table"} shows mortality in thoracolumbar spinal cord injury according to the duration of follow-up. Three studies (16%) reported long-term mortality without explicitly stating the follow-up period. In one study, the follow-up duration was between one week and one year after injury with 6.2% mortality. In three studies including 1279 patients, the mean 1-year mortality was 4.3% (56 patients) \[[@B24]-[@B26]\]. In another recent study, among 147 patients with TLSCI region, the mortality rate of thoracic cases was 5% \[[@B21]\]. Krause *et al*., \[[@B27]\] reported the long-term outcomes of a cohort of patients with average follow-up duration 14.3 (±7.8) months post-injury and the maximum of 11 years; there were 19 deaths in 141 patients (13.5 %).

###### 

Reported Follow-up and Causes of Death in Included Thoracolumbar Spinal Cord Injury Studies.

  **Studies**           **No. patients**   **Duration of shorter follow up period**   **Mortality during  shorter follow up period**   **Duration of longer follow-up** **Period**                                                 **Mortality during  of longer follow-up** **period**   **No. deaths**
  --------------------- ------------------ ------------------------------------------ ------------------------------------------------ ------------------------------------------------------------------------------------------- ------------------------------------------------------ ----------------
  **Krause 1997**       141                \-                                         \-                                               14.3±7.8 yr.post-injury                        11 yr. follow-up                             19                                                     19
  **Levy 1998**         67                 \-                                         \-                                               Hospital discharge - \>1year                                                                13                                                     13
  **Yeo 1998**          650                \<18 months                                35                                               \>18 months                                                                                 78                                                     113
  **O'Connor 2005**     1355                                                                                                           10-year                                                                                     92                                                     92
  **Lidal 2007**        205                \-                                         \-                                               median 27 years (range 20--39 years)                                                        53                                                     53
  **Leal-Filho 2008**   189                (In-hospital)                              0                                                \-                                                                                          \-                                                     0
  **Furlan 2009**       87                 (In-hospital)                              2                                                \-                                                                                          \-                                                     2
  **Divanoglou 2010**   48                 \-                                         \-                                               After 1st week to 1 year                                                                    3                                                      3
  **Furlan 2010**       136                \-                                         \-                                               In the 1st year                                                                             6                                                      6
  **Hagen 2010**        188                \-                                         \-                                               Mean 33 years (7-56)                                                                        59                                                     59
  **Ning 2010**         248                In-hospital                                0                                                \-                                                                                          \-                                                     0
  **Varma 2010**        715                (In-hospital)                              74                                               \-                                                                                          \-                                                     74
  **Krause2011**        402                \-                                         \-                                               minimum of 1 yr. post injury (Mean mortality follow-up: 10.4±7.3)                           84                                                     84
  **Krause2011**        3990               \-                                         \-                                               Average of 7.7 yrs. post-injury (\>1 yr.)                                                   402                                                    402
  **Ahoniemi 2011**     811                \-                                         \-                                               The median length of follow-upwas 12.5 years (interquartile range (IQR) 5.5--19.8 years).   163                                                    163
  **Kawu 2011**         94                 \<6 months                                 32                                               \-                                                                                          \-                                                     32
  **Grossman 2012**     56                 In hospital                                0                                                \-                                                                                          \-                                                     0
  **Middleton.2012**    938                ≤12M                                       38                                               \>12M                                                                                       162                                                    200
  **Cao 2013**          4042               \-                                         \-                                               7.7 years posst inury with the averagefollow-up 9.3 years                                   530                                                    530
  **Nwankwo 2013**      40                 ≤6 months                                  3                                                \-                                                                                          \-                                                     3
  **Sabre2013**         205                \<12M                                      12                                               12M-2yr\>2yr                                                                                329                                                    44
  **Löfvenmark 2014**   20                 In-hospital                                1                                                \-                                                                                          \-                                                     1
  **Barman2014**        367                \-                                         \-                                               NA[a](#TFN25){ref-type="table-fn"}                                                          93                                                     93
  **Hossain 2015**      201                In-hospital                                2                                                2-year                                                                                      23                                                     25
  **Total**             11205                                                         197                                                                                                                                          977                                                    1174

NA: not available

###### 

Mortality in Thoracolumbar Spinal Cord Injury according to the duration of follow-up.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Duration**                                    **Death/SCI** **Number (%)**                       **Author year (Number of studies)**
  ----------------------------------------------- -------------------------------------------------- ----------------------------------------------------------------------------------------
  In hospital                                     79/1516 (5,21)\                                    (Furlan 2005, Furlan 2009, Hossain 2015, Varma 2010, Leal-filho 2008 Löfvenmark 2014 )
                                                  F\                                                 
                                                  F\                                                 
                                                  H: 2/201 (1.0)                                     

  \<6mo.                                          35/134 (26.12)                                     Mean (2)\
                                                                                                     (Nwankwo 2013, Kawn 2011

  \<12mo.                                         55/1279 (4.30)                                     Mean (2) (Midelton 2012, Sabre 2013, Furlan 2010)

  Hospital discharge -- 1-year                    13/45 (28.89)                                      Levy 1998

  \<18mo.                                         35/650 (5.4)                                       Yeo 1998

  from H. discharge to 34.4 month12month-2year\   23/195(11.8)\                                      Hossain 2015\
                                                  3/193(1.5)                                         Sabre 2013

  1y- 5.6y (4.6y=55.6m.- median)                  23/180[\#\#](#TFN28){ref-type="table-fn"} (12.8)   Garshick 2005

  10 yrs.  6.5 y (Mean)                           92/1355 (6.8)                                      O'Connor 2005

  7.7yrs.                                         402/3990 (10.07)                                   Krause 2011

  9.3 yrs.                                        530/4042(13.1)                                     Cao 2013

  10.4 yrs.                                       84/402 (20.89)                                     Krause 2011

  12.5 yrs.                                       163/811(20.09)                                     Ahoniemi 2011

  14 yrs.                                         44/205 (21.46)                                     Sabre 2013

  14.3 yrs.                                       19/141 (13.47)                                     Krause 1997

  27 yrs.                                         53/205(25.8)                                       Lidal 2007

  15yrs.[b](#TFN26){ref-type="table-fn"}          92/337 (27.3)                                      Barman 2014

  From 1.5y to 30yrs.                             78/650-Xa (24.0)                                   Yeo 1998

  32 yrs.                                         59/188 (31.38)                                     Hagenc 2010
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Unknown number of cases with lost to follow-up;

Mean follow-up is 15 years for study between 1981 and 2011; c2001-1952-50; evaluation of individuals with SCI was performed at August 2008 (after 7yrs); Mean follow-up of (25+7=) yrs.32;

others: Lumbosacral

![The mortality rate in Thoracolumbar Spinal Cord Injury studies with determined post-injury follow-up.](bet-6-181-g003){#F3}

*Risk factors for mortality*

 In 13 of the 24 studies, contributing factors for mortality were reported. In all of these studies, the risk factors were assessed for all SCI patients and not for each thoracolumbar subgroup distinctively. Seven studies developed multivariate regression models to adjust for the effects of confounding factors.

*Age and Gender*

 In 14 studies, the association of mortality and gender was assessed; there was no significant association except three studies \[[@B10], [@B27], [@B28]\]. In one of these studies \[[@B27]\], the female gender and in two studies \[[@B10], [@B28]\], the male gender were predominant. In the study by Varma *et al*., \[[@B10]\] gender was not significant by univariate analysis however after adjustment for confounders by multivariable logistic regression modeling, a 60 percent higher chance of death in males compared with females was seen (OR=1.6). In all studies, the association of higher age and mortality was assessed which showed a significant relationship in all except one \[[@B29]\]; this study compared patients less than 20 years old with older subjects.

*The level of lesion and neurologic status*

 Severity of injury as complete or incomplete neurologic deficit or Frankel and ASIA classes was evaluated in 10 studies. Five studies reported completeness of neurologic deficit and the association with death. In all except one study 30, the association was significant. In this study, two groups of 61 and 30 patients were enrolled from Greece and Sudan, respectively; lack of significance may be due to the small sample populations. In the study by Hagen *et al*., \[[@B20]\], Patients with complete traumatic spinal cord injury had higher standardized mortality ratio (SMR) in comparison to incomplete injuries (4.23 vs. 1.25). This higher SMR was also true for spinal lesions at cervical and thoracolumbar level subgroups (3.07 vs. 1.13). In the study by Sabre *et al*., \[[@B24]\], the completeness of lesions was only related to mortality in the first two years after injury. In the other five studies, the severity was assessed by ASIA and Frankel Grades, and its association with mortality was reported. In these studies, the mortality rate was higher in those with Grade A neurological injury.

*Time passed from injury*

 The association of duration of time since injury and mortality was evaluated in 3 studies which did not find any significance \[[@B20], [@B21], [@B27]\].

 *Comorbidities*

 The association of comorbidities with mortality was assessed in 5 studies with significant associations in all studies. One study \[[@B23]\] evaluated comorbidities using three methods including the Charlson Comorbidity Index, some diagnostic ICD-9 codes assigned, and the Cumulative Illness Rating Scale (CIRS); only the Charlson Comorbidity Index exhibited a significant association. One study assessed the incidence of comorbidities \[[@B10]\] and one report assessed mortality \[[@B21]\] according to each risk factor separately; one hyperlipidemia reached significance. In one study, only comorbidities related to spinal diseases was considered \[[@B30]\].

*Associated injuries*

 Traumatic co-injuries were assessed in three studies \[[@B24], [@B25], [@B30]\] and in one study, a concomitant head injury was significant just within the first two years after injury \[[@B24]\]. The association of treatment method with mortality was assessed in three studies \[[@B24], [@B25], [@B30]\] and was significant in one \[[@B24]\]. In this study, the death rate in the first two years after injury was lower in those who underwent operations within the first six weeks after injury. The other risk factors are presented in [Table 7](#T7){ref-type="table"}.

###### 

Risk Factors for Mortality in Spinal Cord Injury Studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Studies**                **Risk Factor**                                          **Comparison**                                                                                   **Significance**                                                                                                                                                                                                                                                **Risk Factors** **Adjusted for** **Confoundingfactors**
  -------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------
  **Krause 1997**            Male\                                                    Female\                                                                                          NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             No
                             Age(continuous)\                                         -\                                                                                               p=≤ 0.001\                                                                                                                                                                                                                                                      
                             Complete\                                                Incomplete                                                                                       P=≤0.05\                                                                                                                                                                                                                                                        
                             Economic Satisfaction\                                                                                                                                    NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Employment Status                                                                                                                                         P=≤ 0.05                                                                                                                                                                                                                                                        

  **Furlan 2009**            Male\                                                    Female\                                                                                          NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             Yes
                             Age (continuous)\                                                                                                                                         P=0.0002\                                                                                                                                                                                                                                                       
                             duration of the initial hospitalization\                                                                                                                  NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             ASIA Scale\                                                                                                                                               0.01\                                                                                                                                                                                                                                                           
                             Charlson Co-morbidity Index\                                                                                                                              P= 0.005\                                                                                                                                                                                                                                                       
                             Number of ICD-9[d](#TFN30){ref-type="table-fn"} codes\                                                                                                    NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Cumulative Illness Rating Scale                                                                                                                           NS[b](#TFN28){ref-type="table-fn"}                                                                                                                                                                                                                              

  **Divanoglou 2010**        Male\                                                    Female\                                                                                          NS[b](#TFN26){ref-type="table-fn"}P= 0.003NS[b](#TFN28){ref-type="table-fn"}NS[b](#TFN28){ref-type="table-fn"}NS[b](#TFN28){ref-type="table-fn"}P= 0.04NS[b](#TFN28){ref-type="table-fn"}                                                                       No
                             Mean age mortality cases\                                Mean age survival cases\                                                                                                                                                                                                                                                                                                                                         
                             Complete\                                                incomplete\                                                                                                                                                                                                                                                                                                                                                      
                             Transportation-related injury\                           No Transportation-related injury\                                                                                                                                                                                                                                                                                                                                
                             Serious extra spinal injuries\                           No Serious extra spinal injuries\                                                                                                                                                                                                                                                                                                                                
                             Comorbid spinal disease\                                 No Comorbid spinal disease\                                                                                                                                                                                                                                                                                                                                      
                             Surgery                                                  No surgery                                                                                                                                                                                                                                                                                                                                                       

  **Furlan 2010**            Male\                                                    Female\                                                                                          NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             No
                             Age(continuous)\                                         incompleteNon-whiteNot MVA\                                                                      P=\<0.0001\                                                                                                                                                                                                                                                     
                             Complete\                                                No Drug intervention (placebo or drug)No Co-intervention (surgical or conservative management)   P=0.02\                                                                                                                                                                                                                                                         
                             White\                                                                                                                                                    NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             MVA\                                                                                                                                                      NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             GCS^f^\                                                                                                                                                   NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Drug intervention (placebo or drug)\                                                                                                                      NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Co-intervention (surgical or conservative management)                                                                                                     NS[b](#TFN28){ref-type="table-fn"}                                                                                                                                                                                                                              

  **Hagen 2010**             FemaleComplete\                                          Male Incomplete                                                                                  P=0.002P=\<0.001\                                                                                                                                                                                                                                               Yes
                             Age(per 10 year increase)\                                                                                                                                P=\<0.001\                                                                                                                                                                                                                                                      
                             Time period (Per 10 year increase.)                                                                                                                       NS[b](#TFN28){ref-type="table-fn"}                                                                                                                                                                                                                              

  **Varma 2010**             Male\                                                    Female\                                                                                          P= 0.016\                                                                                                                                                                                                                                                       Yes
                             Age in \<20y age group\                                   Frankel B\                                                                                      NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Age in \>20y age group\                                  No white\                                                                                        P\<0.0001\                                                                                                                                                                                                                                                      
                             Frankel A\                                               0\                                                                                               P=0.015\                                                                                                                                                                                                                                                        
                             white\                                                   ISS :mild-moderate\                                                                              NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             number of comorbidities (1,2&3)\                         No TBI\                                                                                          P\<0.0001\                                                                                                                                                                                                                                                      
                             ISS[h](#TFN34){ref-type="table-fn"} :severe\             Trauma center level 2                                                                            P= 0.012\                                                                                                                                                                                                                                                       
                             TBI[i](#TFN35){ref-type="table-fn"}\                                                                                                                      P=\< 0.0001\                                                                                                                                                                                                                                                    
                             Trauma center level 1                                                                                                                                     P=0.026                                                                                                                                                                                                                                                         

  **Krause 2011**            Male\                                                    Female\                                                                                          NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             yes
                             Age (continuous)\                                        Ambulatory\                                                                                      P=\<0.0001\                                                                                                                                                                                                                                                     
                             Injury severity:\                                        ambulatory\                                                                                      P=\<0.0001\                                                                                                                                                                                                                                                     
                             In cervicalIn non-cervical\                              -\                                                                                               NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Years since injury\                                      never get them\                                                                                  NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             PUs[j](#TFN36){ref-type="table-fn"}/YES\                 NO\                                                                                              P=\<0.0001\                                                                                                                                                                                                                                                     
                             PMD[d](#TFN30){ref-type="table-fn"}/YES\                 NO                                                                                               P=0.0009\                                                                                                                                                                                                                                                       
                             Hospitalizations                                \                                                                                                         P=0.0006                                                                                                                                                                                                                                                        
                                ≥1                                                                                                                                                                                                                                                                                                                                                                                                                     

  **Kawu 2011**              Mean age mortality cases\                                Mean age\                                                                                        P=0.001\                                                                                                                                                                                                                                                        No
                             Frankel A\                                               survival cases\                                                                                  P=0.001\                                                                                                                                                                                                                                                        
                             GCS[f](#TFN32){ref-type="table-fn"}\<9                   -\                                                                                               P=0.001                                                                                                                                                                                                                                                         
                                                                                      -                                                                                                                                                                                                                                                                                                                                                                

  **Grossman 2012**\         Mean age mortality cases\                                Mean age survival cases\                                                                         P=0.038\                                                                                                                                                                                                                                                        NO
                             concurrent morbidities/YES                               NO                                                                                               P=0.01                                                                                                                                                                                                                                                          

  **Krause 2012**            Male\                                                    Female\                                                                                          CI:1.05--1.46\                                                                                                                                                                                                                                                  YES
                             35-39\                                                   18--34 Y\                                                                                        CI :1.36--2.39\                                                                                                                                                                                                                                                 
                             40-44\                                                   18--34 Y\                                                                                        CI :1.74--2.95\                                                                                                                                                                                                                                                 
                             45-49\                                                   18--34 Y\                                                                                        CI :2.40--4.00\                                                                                                                                                                                                                                                 
                             50-54\                                                   18--34 Y\                                                                                        CI :3.21--5.44\                                                                                                                                                                                                                                                 
                             55-59\                                                   18--34 Y\                                                                                        CI :3.96--7.01\                                                                                                                                                                                                                                                 
                             60-64\                                                   18--34 Y\                                                                                        CI :4.22--8.01\                                                                                                                                                                                                                                                 
                             65-69\                                                   18--34 Y\                                                                                        CI :7.33--13.60\                                                                                                                                                                                                                                                
                             70-74\                                                   18--34 Y\                                                                                        CI :10.98--20.86\                                                                                                                                                                                                                                               
                             75-79\                                                   18--34 Y\                                                                                        CI :17.57--36.37\                                                                                                                                                                                                                                               
                             \>80\                                                    18--34 Y\                                                                                        CI :23.70--52.14\                                                                                                                                                                                                                                               
                             C1--C4\                                                  Non-cervical\                                                                                    CI :2.09--3.06\                                                                                                                                                                                                                                                 
                             C5--C8\                                                  Non-cervical\                                                                                    CI :1.74--2.41\                                                                                                                                                                                                                                                 
                             White\                                                   other\                                                                                           CI :1.00--1.74\                                                                                                                                                                                                                                                 
                             Black\                                                   other\                                                                                           CI :1.24--1.87\                                                                                                                                                                                                                                                 
                             Violence & other\                                        MVC/FL/Spc\                                                                                      NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             AIS[k](#TFN37){ref-type="table-fn"}/Frankel A\           AISk/Frankel D/E\                                                                                CI :1.37--2.37\                                                                                                                                                                                                                                                 
                             AIS[k](#TFN37){ref-type="table-fn"}/Frankel B & c\       AISk/Frankel D/E\                                                                                NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Low Income\                                              High Income\                                                                                     CI :1.76--3.02\                                                                                                                                                                                                                                                 
                             Middle Income\                                           High Income\                                                                                     CI :1.23--2.12\                                                                                                                                                                                                                                                 
                             Education \>Bachelors\                                   \< High School\                                                                                  CI :0.45--0.71\                                                                                                                                                                                                                                                 
                             Education High School/Associates                         \< High School                                                                                   CI :0.69--0.96                                                                                                                                                                                                                                                  

  **Rabadi 2013**            Male\                                                    Female\                                                                                          NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             YES
                             Age (continuous)\                                         \                                                                                               P=\<0.0001\                                                                                                                                                                                                                                                     
                             Ethnicity (White/Black/American Indian/Hispanic )\        \                                                                                               NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Duration since SCI[a](#TFN27){ref-type="table-fn"}\                                                                                                       NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Spinal injury level\                                                                                                                                      NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Severity of injury (AIS Grade)\                                                                                                                           NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Etiology of SCI[a](#TFN27){ref-type="table-fn"}\                                                                                                          NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Hypertension/DM[l](#TFN38){ref-type="table-fn"}\                                                                                                          NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Hyperlipidemia\                                                                                                                                           P=0.01\                                                                                                                                                                                                                                                         
                             Vascular risk factors\                                                                                                                                    NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Myocardial infarction\                                                                                                                                    P=0.006\                                                                                                                                                                                                                                                        
                             Congestive heart failure\                                                                                                                                 NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Depression\                                                                                                                                               P=0.005\                                                                                                                                                                                                                                                        
                             Pressure ulcers\                                                                                                                                          NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Neurogenic bowel /bladder                                                                                                                                 NS[b](#TFN28){ref-type="table-fn"}                                                                                                                                                                                                                              

  **Sabre 2013**\            Male\                                                    Female\                                                                                          NS[b](#TFN28){ref-type="table-fn"}P=\<0.001NS[b](#TFN28){ref-type="table-fn"}NS[b](#TFN28){ref-type="table-fn"}NS[b](#TFN28){ref-type="table-fn"}NS[b](#TFN28){ref-type="table-fn"}P=0.005P=\<0.001P=\<0.001P=\<0.001NS[b](#TFN28){ref-type="table-fn"} 0.004   NO
  **≤2 years after TSCI**    Age at injury(continuous)\                               -\                                                                                                                                                                                                                                                                                                                                                               
                             Year of injury\                                          -\                                                                                                                                                                                                                                                                                                                                                               
                             Assault/Traffic accident/falls\                          Sport\                                                                                                                                                                                                                                                                                                                                                           
                             Preinjury alcohol consumption/YES\                       NO\                                                                                                                                                                                                                                                                                                                                                              
                             Concomitant injury/YES\                                  NO\                                                                                                                                                                                                                                                                                                                                                              
                             Head injury/YES\                                         NO\                                                                                                                                                                                                                                                                                                                                                              
                             C1--4 & C5--8Incomplete\                                 T1--S5\                                                                                                                                                                                                                                                                                                                                                          
                             Operation in 6 weeks/YES\                                Complete\                                                                                                                                                                                                                                                                                                                                                        
                             Methylprednisolone in acute phase/YES\                   NO\                                                                                                                                                                                                                                                                                                                                                              
                             Complication in acute phase/YES                          NO\                                                                                                                                                                                                                                                                                                                                                              
                                                                                      NO                                                                                                                                                                                                                                                                                                                                                               

  **\>2 years after TSCI**   Male\                                                    Female\--SportsportNONONOT1--S5completeNONONO                                                    NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Age at injury(continuous)\                                                                                                                                P=\<0.001\                                                                                                                                                                                                                                                      
                             Year of injury\                                                                                                                                           NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Assault/Traffic accident\                                                                                                                                 NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Falls\                                                                                                                                                    P=0.004\                                                                                                                                                                                                                                                        
                             Preinjury alcohol consumption/YES\                                                                                                                        NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Concomitant injury/YES\                                                                                                                                   NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Head injury/YES\                                                                                                                                          NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             C1--4 & C5--8\                                                                                                                                            NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Incomplete\                                                                                                                                               NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Operation in 6 weeks/YES\                                                                                                                                 NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Methylprednisolone in acute phase/YES\                                                                                                                    NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             Complication in acute phase/YES                                                                                                                           NS[b](#TFN28){ref-type="table-fn"}                                                                                                                                                                                                                              

  **Barman 2014**            Male\                                                    Female\                                                                                          NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             YES
                             Age(continuous)\                                         MVC\                                                                                             NS[b](#TFN28){ref-type="table-fn"} \                                                                                                                                                                                                                            
                             Fall\                                                    MVC\                                                                                             CI:1.16-3.18\                                                                                                                                                                                                                                                   
                             Others\                                                  L1-S5\                                                                                           CI:1.56-5.15\                                                                                                                                                                                                                                                   
                             C1-4\                                                    L1-S5\                                                                                           CI:1.87-8.15\                                                                                                                                                                                                                                                   
                             C5-8\                                                    L1-S5\                                                                                           CI:1.01-4.05\                                                                                                                                                                                                                                                   
                             T1-6\                                                    L1-S5\                                                                                           CI:1.05-4.02\                                                                                                                                                                                                                                                   
                             T7-12\                                                   D\                                                                                               NS[b](#TFN28){ref-type="table-fn"}\                                                                                                                                                                                                                             
                             AIS[k](#TFN37){ref-type="table-fn"} grade A\             D\                                                                                               CI:3.23-168.15\                                                                                                                                                                                                                                                 
                             AIS[k](#TFN37){ref-type="table-fn"} grade B\             D                                                                                                CI:2.73-148.91NS[b](#TFN28){ref-type="table-fn"}                                                                                                                                                                                                                
                             AIS[k](#TFN37){ref-type="table-fn"} grade C                                                                                                                                                                                                                                                                                                                                                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SCI: spinal cord injury;

NS=not significant;

MVC/FL/Sp =motor vehicle crash/fall/sports;

PMD= probable major depression;

ICD-9: International Statistical Classification of Diseases and Related Health Problems-9th revision;

GCS: Glasgow Coma Scale;

PEC: Preexisting co-morbidity;

ISS: injury severity score;

TBI: traumatic brain injury;

PUs: pressure ulcers;

AIS: American Spinal Injury Association Impairment Scale;

DM: diabetes mellitus.

We did not consider the data of Levy 1998 because of unknown period for mortality (13/67), the significant number of non-responder patients with SCI and discrepancy between information in the text and figure \[[@B19]\].

Discussion
==========

The goal of this systematic review was to evaluate the rate of mortality and its contributing factors in patients with TLSCI. In another systematic review, we assess mortality in the cervical region and by comparing the results of both systematic reviews we could have a better understanding of epidemiology and burden of traumatic spinal cord injury. Due to the heterogeneity of the studies on factors such as follow-up duration and cohort size, it is not possible to form a general conclusion. Also, because of a general dearth of reports on pre-hospital mortality and the fact that only subjects who survived the trauma were included, the mortality rate is lower than the real rate. The reported mortality rate ranges from 0% to 37.7%. This wide range is due to inhomogeneity between study designs. Studies with higher mortality had longer follow-up periods in general and, because the exact cause of death was typically not mentioned, it may not be due to TLSCI itself. Nonetheless, the SCI does affect the function of many other organ systems in the long run as indicated by reports of accelerated cardiovascular disease in SCI patients.

In studies reporting in-hospital mortality, the overall mortality rate was 5.2%; in studies reporting 6-month mortality, the overall rate was 26.12%, and in studies reporting 1-year mortality, the overall rate was 4.3%. In a systematic review by Chamberlain *et al*., the pooled in-hospital mortality rate among all traumatic SCI patients was 8% \[[@B31]\]. The significant differences between overall rates for in-hospital, 6-month and 1-year mortality may be because the 6-month mortality reports were from underdeveloped countries, which emphasizes the role of health system quality in mortality. In the studies from more developed countries with more advanced medical systems, mortality rates were lower. For example, comparing two studies with a similar follow-up period, the report from Nigeria (1997-2007) reported a 34% mortality rate after 6-months follow-up \[[@B32]\] while a study from the USA (1998-2008) reported 20% mortality with a minimum follow-up period of 1 year \[[@B27]\]. Although the cause of death was reported, in those with TLSCI the cause was available only in two studies. For a thorough assessment of the effects of the treatment on mortality, it is recommended that future studies report the cause of death during hospital admission and long-term follow-up.

Age at admission was described in all report. The association of age with mortality was significant in all except one study which reported higher but nonsignificant hazard ratio (HR) with increasing age. The authors hypothesized this was due to a higher severity of injury in the younger subjects and lower severity in older patients. In a meta-analysis by Chamberlain et al., pooled estimates of HRs and ORs of 1.06 (1.05--1.07; I2 = 78.2%) and 1.06 (1.03--1.09; I2 = 94.6%) for age at injury for all traumatic spinal cord injuries showed moderate-to-high heterogeneity, indicating that mortality risk increases on average by 6% with increasing age \[[@B31]\]. Although injury of a higher spinal level is associated with higher mortality rates, the studies did not differentiate between thoracic and lumbar injuries. The study by Cotton *et al*. involving 596 patients with thoracic SCI revealed that patients with high-thoracic SCI have 1.5-fold higher mortality probability compared with SCI of lower thoracic region and 3.45-fold higher compared with lumbar SCI \[[@B33]\].

There is also increased mortality in complete versus incomplete lesions. For example, Hagen et al. reported 23% and 38.6% mortality in incomplete and complete TLSCI, respectively. This study evaluated all individuals with SCI however and not TLSCI specifically. Duration of time after injury showed no significant association with mortality \[[@B20], [@B21], [@B27]\]. Considering the effects of comorbidities and associated injuries in patients with spinal injuries may help in defining mortality risk factors. These factors were related to higher mortality rates in some studies, and it seems in-hospital mortality in TLSCI may be more dependent on associated injuries and comorbidities than cervical SCI.

The presence or count of comorbidities by diagnostic code was not useful in differentiating mild and severe injuries. Tools such as the premorbid illnesses criteria and the Charlson Comorbidity Index were more useful for comparison purposes and are recommended for further studies. Divanoglou 2010 performed a cohort of population based study from 1-week to 1-year and found related mortalities \[[@B30]\]. We did not consider their study in our figure because of the inhomogeneous time interval of 1-week to 1-year.

In the systematic review (SR) of van den Berg et al., they assessed survival of patients with SCI, there were 11 out of 16 studies with traumatic SCI, four with non-traumatic and one both \[[@B34]\].  Therefore, the SR was a mixture of traumatic and non-traumatic patients with involvement of all cervical, thoracic and lumbar levels \[[@B34]\]. In the traumatic SCI population, survival rates up to 5 years post-injury ranged from 94.6% to 99.0% (mean 5-year survival rate 97.0±1.85) \[[@B34]\]. In another SR, Wilson et al., have combined three components of outcome to include survival, functional and neurological recovery \[[@B35]\]. They included traumatic SCI. However, they did not perform analysis for survival or mortality and did not extract the data of patients with thoracolumbar levels from all patients with SCI.

The most significant limitation of this systematic review is that no study exclusively assessed mortality rate and causes of death and risk factors in TLSCI patients. Some other limitations include: 1) the systematic review of observational studies is controversial \[[@B15], [@B16]\]. Despite the use of some criteria for quality assessment in some recent systematic reviews \[[@B15], [@B16], [@B36]\], their choice status is not clear yet; 2) observational studies are sensitive to selection, detection, confounders, performance bias, and publication bias; 3) Non-English reports were excluded which may result in the omission of some relevant studies; and 4) Types of treatment, severity of injury, patients medical status, mechanism of traumatic injury, and follow-up duration differed across the selected studies. These variations, especially in follow-up time, may contribute to the discrepancies in outcomes of the studies. In our review, a meta-analysis was not performed due to the limited number of selected studies, varying definitions of short- and long-term follow-up, and the general absence of reports on the mean follow-up duration.

Conclusion
==========

Despite the importance of TLSCI, related epidemiological data such as mortality and contributing factors remain unclear. Although there is general agreement that traumatic thoracolumbar spinal cord injuries are important, no study was found that accurately assessed mortality in the thoracolumbar spine. It is recommended that well-designed prospective observational studies be conducted to determine the mortality rate and exact causes of death in thoracolumbar injuries.
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